Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Povorcitinib Phosphate Tablets in Chinese Adult Participants With Nonsegmental Vitiligo

NCT07865312 is registered in ClinicalTrials.gov with Dermavon Holdings Limited as lead sponsor.

NCT NCT07865312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07865312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Povorcitinib Phosphate Tablets in Chinese Adult Participants With Nonsegmental Vitiligo
Lead sponsor
Dermavon Holdings Limited
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
June 30, 2028
Enrollment
174 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

nonsegmental vitiligo